Zhejiang Shapuaisi Pharmaceutical (603168.SH): Olodaterol hydrochloride eye drops obtained drug registration certificate
Shapuaisi (603168.SH) announced that the company has received approval from the National Medical Products Administration for the issuance of hydrochloride...
Zhejiang Shapuaisi Pharmaceutical (603168.SH) announced that the company has received the Drug Registration Certificate for Olopatadine Hydrochloride Eye Drops approved and issued by the National Medical Products Administration. The approved Olopatadine Hydrochloride Eye Drops are used to treat eye itching related to allergic conjunctivitis.
Related Articles
HK Stock Market Move | NVIDIA GTC leads the way "first stock of Token" XUNCE (03317) soared more than 5% in the morning, the company deeply seizes the value gap of AI data.
CMA LOGISTICS (01292) expects the net profit attributable to the parent company to be approximately 37 to 43 million yuan in 2025, a decrease of about 38.27% to 28.27% year-on-year.
MNSO (09896) spent $233,800 to repurchase 54,700 shares on March 16th.
HK Stock Market Move | NVIDIA GTC leads the way "first stock of Token" XUNCE (03317) soared more than 5% in the morning, the company deeply seizes the value gap of AI data.
CMA LOGISTICS (01292) expects the net profit attributable to the parent company to be approximately 37 to 43 million yuan in 2025, a decrease of about 38.27% to 28.27% year-on-year.
MNSO (09896) spent $233,800 to repurchase 54,700 shares on March 16th.
